Cross-linked polyacrylic acid polymer integrated eutectogel formulation for transdermal and localised drug delivery
Patent Information
- Application Number
- IN202621014455
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2026-02-10
- Publication Date
- 2026-10-28
- Estimated Expiration
- 2046-02-10
AI Technical Summary
Conventional pharmaceutical gels for drug delivery face challenges such as poor solubility of hydrophobic drugs, limited injectability, requirement of chemical cross-linkers, low mechanical recovery, instability under physiological conditions, susceptibility to evaporation, reduced mechanical stability, and low ionic conductivity, making them unsuitable for non-aqueous environments and prone to freezing.
A cross-linked polyacrylic acid polymer integrated eutectogel formulation using a deep eutectic solvent physically cross-linked with carbopol, eliminating the need for chemical cross-linkers, and providing self-healing, injectability, and controlled drug release.
The eutectogel exhibits self-healing behavior, injectability through a standard gauge needle, thermal stability up to 150°C, sustained drug release of approximately 90% over 24 hours, antibacterial activity, cytocompatibility, and hemocompatibility, suitable for transdermal and localized drug delivery applications.
Abstract
Description
FIELD OF INVENTION
[0001] The present invention relates to pharmaceutical gel formulations for drug delivery.Particularly, the present invention relates to a cross-linked polyacrylic acid polymer integrated eutectogelformulation for transdermal and localised drug delivery. More particularly, the present invention relates toa eutectogel formulation prepared using an environmentally benign deep eutectic solvent composed of ahydrogen bond acceptor and a hydrogen bond donor, physically cross-linked with a cross-linked polyacrylicacid polymer, to form a stable, biocompatible, self-healing, and injectable gel template, eliminating theneed for chemical cross-linkers and enabling sustained and controlled drug release.BACKGROUND OF THE INVENTION
[0002] Pharmaceutical gel formulations have become increasingly important in the field of drugdelivery systems, particularly for transdermal and localised therapeutic applications. Such gels haveevolved significantly to address multiple drug delivery challenges through advanced formulations. Moderndrug delivery systems increasingly incorporate gel-based matrices to provide controlled release, localiseddelivery, and improved bioavailability of active pharmaceutical ingredients. The development of deepeutectic solvents has enabled the creation of novel gel systems with enhanced properties including improveddrug solubility, thermal stability, and biocompatibility.
[0003] Conventional pharmaceutical gels are commonly based on hydrogels, organogels, or polymersolventsystems. These systems suffer from several limitations including poor solubility of hydrophobicdrugs, limited injectability, the requirement of chemical cross-linkers, low mechanical recovery, instabilityunder physiological conditions, susceptibility to evaporation, reduced mechanical stability, and low ionicconductivity. These issues make conventional gels unsuitable for different environments with low humidityor non-aqueous settings, as they are prone to freezing, which can damage their structure. These limitationshave significantly restricted their practical applications.
[0004] Eutectogels, which are gels that rely on deep eutectic solvents, have emerged as a promisingclass of soft materials. These gels are typically formed by incorporating polymer networks, nanoparticles,low-molecular-weight gelators, or cross-linkers into deep eutectic solvents. Eutectogels have gainedwidespread attention due to their exceptional properties including excellent thermal and electrochemicalstability, low volatility, self-healing ability, low cost, and biodegradability.
[0005] There are several patent applications that disclose deep eutectic solvent-based gel systems forpharmaceutical and topical applications.
[0006] One such Chinese Patent Application, CN119019800A discloses a preparation method of apolymerizable eutectic gel conductive elastomer based on supramolecular cross-linking, wherein acrylicacid and choline chloride are mixed, and then aluminum nitrate nonahydrate is added to fully dissolve it,followed by adding amino-terminated hyperbranched aramid and a photoinitiator and dispersing themevenly to obtain a precursor solution, and finally an ion conductive elastomer is obtained by a photocuringcross-linking reaction. However, the cited prior art adopts a photoinitiated free radical polymerizationmethod requiring a photoinitiator (I2959) and ultraviolet irradiation for curing treatment, therebynecessitating chemical cross-linking agents and UV curing equipment rather than achieving a purelyphysically cross-linked network with no demonstration of biocompatibility, antibacterial activity,cytocompatibility, hemocompatibility, or controlled drug release properties essential for transdermal andlocalised drug delivery.
[0007] Another Indian Patent Application, IN202321056078 discloses a deep eutectic solvent-basedanti-fungal muco-adhesive gel for transdermal drug delivery. The formulation includes activepharmaceutical ingredients, hydrogen bond acceptors, hydrogen bond donors, polymers, humectants,surfactants, preservatives, and pH-adjusting agents. The formulation uses a combination of Noveon AA-Iin the range of 1 to 2% w / w and Sodium CMC in the range of 0.5 to 1% as polymers rather than crosslinkedpolyacrylic acid polymers such as carbopol for physical cross-linking. The cited prior art does notdemonstrate self-healing behaviour, injectability through a standard gauge needle, or the combination ofproperties needed for minimally invasive localised drug delivery applications.
[0008] One of the non-patent literatures titled "Formation of Self-Healing Granular Eutectogelsthrough Jammed Carbopol Microgels in Supercooled Deep Eutectic Solvent ; Arjunan et al. (Langmuir,2024) discloses self-healing granular eutectogels formed through jammed Carbopol microgels insupercooled deep eutectic solvents. The deep eutectic solvent is composed of choline chloride and citricacid in a 3:1 molar ratio, and when the microgel (Carbopol) concentration exceeds 2 wt%, the DESundergoes a transition from a liquid to a soft gel state, characterized as a granular eutectogel exhibitingyield stress with storage moduli exceeding loss moduli. The granular eutectogel has the capability to selfhealsimply by being pushed together after being cut into two pieces. However, when choline chloride andethylene glycol DES was utilized to produce the granular eutectogel by incorporating Carbopol, themechanical strength of the resulting gel was relatively weak. Furthermore, the cited prior art focuses onsupercooled systems for applications such as gel electrolytes, wearable electronic devices, and healthmonitoring sensors and does not address pharmaceutical drug loading, sustained release kinetics, orbiocompatibility assessments necessary for transdermal and localised drug delivery applications.
[0009] Another non-patent literature titled "Eutectogels: The Multifaceted Soft Ionic Materials ofTomorrow" Mercadal et al. (JACS Au, 2024) provided a comprehensive review of eutectogels asmultifaceted soft ionic materials. This innovative class of materials consists of a eutectic solventimmobilized in a three-dimensional network structure, exhibiting key characteristics includingenvironmental friendliness, facile preparation, low vapor pressure, and good ionic conductivity. Moreover,they can be tailored to display functionalities such as self-healing capability, adhesiveness, and antibacterialproperties. However, hydrogels face limitations such as susceptibility to evaporation, reduced mechanicalstability, and low ionic conductivity, making them unsuitable for environments with low humidity ornonaqueous settings and prone to freezing, damaging their structure. The cited prior art provides a generaloverview of eutectogel applications in CO2 separation, batteries, biocatalysis, and food packaging but doesnot demonstrate a specific formulation combining a deep eutectic solvent with cross-linked polyacrylic acidpolymer for transdermal drug delivery with simultaneous self-healing, injectability, and controlled drugrelease properties.
[0010] Yet another non-patent literature titled "Eutectogel-Based Drug Delivery: An InnovativeApproach for Atenolol Administration" Ferrara et al. (Pharmaceutics, 2024) disclosed eutectogel-baseddrug delivery systems for transdermal delivery of atenolol. The study proposes the preparation of a DESbased on choline chloride and propylene glycol to favor the solubility of atenolol, investigating thepreparation of eutectogels derived from the aforementioned deep eutectic solvents with the objective ofimproving the transdermal delivery of the drug. Carbomer, a cross-linked polyacrylic acid polymer withhigh molecular weight and hydrophilic behavior, forms a physical hydrogel with a three-dimensionalpolymer network. However, the cited prior art utilizes propylene glycol as the hydrogen bond donor, whichpresents an entirely different physicochemical environment compared to ethylene glycol-based systems.Additionally, the eutectogel with carbomer released 85.06% of the drug after three days, which does notdemonstrate the combination of self-healing behaviour, injectability, and sustained drug release over 24hours as achieved by the present invention.
[0011] Conventionally existing eutectogel formulations often require chemical cross-linkers oradditional components such as acrylic acid for gel formation. Some other existing systems utilise differenthydrogen bond donors such as citric acid or propylene glycol, which present entirely differentphysicochemical environments. Some of the conventionally available formulations frequently lack thecombination of properties needed to provide simultaneous self-healing, injectability, transparency, andcontrolled drug release in a single stable formulation. Some of the existing products fail to deliver sustaineddrug release while maintaining biocompatibility across different applications.
[0012] Keeping in view the challenges associated with the above state of art, there is a need for aneutectogel formulation that combines a deep eutectic solvent with a cross-linked polyacrylic acid polymer ina single stable formulation without requiring chemical cross-linkers, while providing multifunctionalbenefits including self-healing capability, injectability, controlled drug release, and biocompatibility fortransdermal and localised drug delivery applications.OBJECTIVES OF THE PRESENT INVENTION
[0013] The primary objective of the present invention is to provide a cross-linked polyacrylic acidpolymer integrated eutectogel formulation for transdermal and localised drug delivery and method forpreparation thereof.
[0014] Another objective of the present invention is to provide an eutectogel comprising a deepeutectic solvent physically cross-linked with a cross-linked polyacrylic acid polymer that deliverscontrolled and sustained drug release in a single stable formulation without requiring chemical crosslinkers.
[0015] Another objective of the present invention is to provide a eutectogel formulationwherein carbopol serves as the cross-linked polyacrylic acid polymer for physical cross-linking with thedeep eutectic solvent to form a stable three-dimensional gel network.
[0016] Another objective of the present invention is to provide a eutectogel formulation that achievessimultaneous self-healing capability, injectability, transparency, and long-term stability without phaseseparation.
[0017] Another objective of the present invention is to provide a eutectogel formulation that utilizesa deep eutectic solvent to enhance solubility of hydrophobic or poorly soluble drugs, thereby improvingdrug loading capacity and bioavailability.
[0018] Another objective of the present invention is to provide a eutectogel formulation thatincorporates a synergistic combination of deep eutectic solvent and cross-linked polyacrylic acid polymerto support mechanical integrity and sustained drug release through dynamic noncovalent interactions.
[0019] Another objective of the present invention is to provide a eutectogel formulation that exhibitsantibacterial activity, cytocompatibility, and hemocompatibility, confirming its biocompatibility for topicaland transdermal drug delivery applications.
[0020] Yet another objective of the present invention is to provide a eutectogel formulation thateliminates the need for chemical cross-linkers and toxic catalysts by utilising physical entanglement for gelformation.
[0021] Other objects and advantages of the present invention will become apparent from the followingdescription.SUMMARY OF THE INVENTION
[0022] The present invention relates to a cross-linked polyacrylic acid polymer integrated eutectogelformulation for transdermal and localised drug delivery. The formulation comprises a deep eutectic solventin a range of 95.5 - 97.4% by total weight of the formulation; comprising a hydrogen bond acceptor and ahydrogen bond donor in a molar ratio ranging from 1:1.5 to 1:2.5, a cross-linked polyacrylic acid polymerin a range of 2.5% to 3.5% by total weight of the formulation, and optionally a pharmaceutically activeagent in a range of 0.1 - 1.0% by total weight of the formulation. The cross-linked polyacrylic acid polymeris physically cross-linked with the deep eutectic solvent to form a stable, biocompatible, self-healing, andinjectable gel template without requiring chemical cross-linkers.The method for preparing the eutectogel formulation comprises the steps of: preparing a deep eutecticsolvent by mixing a hydrogen bond acceptor with a hydrogen bond donor in a molar ratio ranging from1:1.5 to 1:2.5; heating the prepared mixture at a temperature ranging from 70°C to 90°C for 1-3 hours toform a clear and homogeneous stable liquid; adding cross-linked polyacrylic acid polymer in the mixtureobtained in step (b) in the molar ratio of 0.007-0.10 under constant stirring to obtain a uniform dispersion;optionally dissolving of 0.1 - 1.0% of pharmaceutically active agent in the mixture obtained in step (c) bystirring to ensure complete solubilization; heating the mixture obtained in step (c) or step (d) at atemperature ranging from 110°C to 140°C for 20-40 minutes; and allowing the mixture obtained in step (e)to cool to room temperature to form the cross-linked polyacrylic acid polymer integrated eutectogelformulation.The eutectogel formulation exhibits self-healing behaviour, injectability through a standard gauge needle,thermal stability up to approximately 150°C, sustained drug release of approximately 90% over 24 hours,antibacterial activity, cytocompatibility, and hemocompatibility, thereby providing a multifunctionalplatform for transdermal and localised drug delivery applications.BRIEF DESCRIPTION OF FIGURES
[0023] The present invention will be better understood after reading the following detailed descriptionof the presently preferred aspects thereof with reference to the appended drawings, in which the features,other aspects and advantages of certain exemplary embodiments of the invention will be more apparentfrom the accompanying drawing in which:
[0024] Figure. 1 illustrates the method for preparing cross-linked polyacrylic acid polymer integratedeutectogel formulation.
[0025] Figure. 2 illustrates the spectral and microscopic profile of the prepared eutectogel, showingthe FT-IR spectrum and SEM micrographs.
[0026] Figure. 3 illustrates (a) the TGA curve and (b) the DSC thermogram of the prepared eutectogel.
[0027] Figure. 4 illustrates (a) frequency sweep analysis, (b) oscillatory strain sweep analysis, and (c)alternate step strain sweeps demonstrating self-healing behaviour of the prepared eutectogel.
[0028] Figure. 5 illustrates (a) photographs of the self-healing process and (b) the injectability througha needle of the prepared eutectogel.
[0029] Figure. 6 illustrates the cumulative drug release profile of lidocaine from the eutectogelformulation.
[0030] Figure. 7 illustrates the zone of inhibition assay of neat eutectogel and drug-loaded eutectogelagainst bacterial strains.
[0031] Figure. 8 illustrates the in vitro cytotoxicity assay of neat eutectogel and drug-loadedeutectogel.
[0032] Figure. 9 illustrates the hemolysis assay results showing hemocompatibility of the referencecompounds with neat eutectogel and drug-loaded eutectogel.DETAILED DESCRIPTION OF THE INVENTION
[0033] The following description describes various features and functions of the disclosed system.The illustrative aspects described herein are not meant to be limiting. It may be readily understood thatcertain aspects of the disclosed system can be arranged and combined in a wide variety of differentconfigurations, all of which have not been contemplated herein.
[0034] Accordingly, those of ordinary skill in the art will recognize that various changes andmodifications of the embodiments described herein can be made without departing from the scope ofinvention. In addition, descriptions of well-known functions and constructions are omitted for clarity andconciseness.
[0035] Features that are described and / or illustrated with respect to one embodiment may be used inthe same way or in a similar way in one or more other embodiments and / or in combination with or insteadof the features of the other embodiments.
[0036] The terms and words used in the following description are not limited to the bibliographicalmeanings, but are merely used to enable a clear and consistent understanding of the invention. Accordingly,it should be apparent to those skilled in art that the following description of exemplary embodiments of thepresent invention are provided for illustrative purposes only and not for the purpose of limiting theinvention.
[0037] It is to be understood that the singular forms "a", "an" and "the" include plural referents unlessthe context clearly dictates otherwise.
[0038] It should be emphasized that the term "comprises / comprising" when used in this specificationis taken to specify the presence of stated features, steps or components but does not preclude the presenceor addition of one or more other features, steps, components or groups thereof.
[0039] Accordingly, the present invention relates to pharmaceutical gel formulations for drugdelivery. Particularly, the present invention relates to a cross-linked polyacrylic acid polymer integratedeutectogel formulation for transdermal and localised drug delivery. More particularly, the present inventionrelates to a eutectogel formulation prepared using an environmentally benign deep eutectic solventcomposed of a hydrogen bond acceptor and a hydrogen bond donor, physically cross-linked with a crosslinkedpolyacrylic acid polymer, to form a stable, biocompatible, self-healing, and injectable gel template,eliminating the need for chemical cross-linkers and enabling sustained and controlled drug release.
[0040] In an embodiment, the eutectogel formulation of the present invention comprises of thefollowing:
[0041] (a) Deep Eutectic Solvent - The formulation comprises a deep eutectic solvent that serves asthe solvent medium providing high solubilization power for hydrophobic or poorly soluble drugs, thermalstability, low volatility, and biocompatibility. The deep eutectic solvent is prepared using a combination ofa hydrogen bond acceptor and a hydrogen bond donor. In an exemplary embodiment, deep eutectic solventused in the present invention may be selected from a group comprising such as, but not limited to, Ethaline.Ethaline is prepared from a combination of choline chloride as hydrogen bond acceptor and ethylene glycolas hydrogen bond donor. In an exemplary embodiment, Ethaline comprises of choline chloride and ethyleneglycol in a ratio of 1:1.5-2.5. In a preferred embodiment, Ethaline comprises of choline chloride andethylene glycol in a ratio of 1:2. In another exemplary embodiment, the deep eutectic solvent is present ina range of 95.5 - 97.4% by total weight of formulation.
[0042] (b) Cross-linked Polyacrylic Acid Polymer- The formulation comprises of cross-linkedpolyacrylic acid polymer serving as a physical cross-linking polymer to form the gel network. Physicalcross-linking eliminates the need for chemical cross-linkers and toxic catalysts, thereby enabling a green,solvent-free fabrication route. In an exemplary embodiment, the cross-linked polyacrylic acid polymer maybe selected from a group comprising such as, but not limited to, carbopol. Carbopol used in the formulationserves as a physical cross-linking polymer that forms a stable three-dimensional gel network throughphysical entanglement with the deep eutectic solvent. The carbopol forms hydrogen bonding interactionswith the deep eutectic solvent, creating dynamic noncovalent cross-links that are responsible for the selfhealingand thixotropic behaviour of the eutectogel. The carbopol contributes to the mechanical integrity,transparency, and long-term stability of the eutectogel formulation. In a preferred embodiment, carbopol940 is used as cross-linked polyacrylic acid polymer in the present invention. In another exemplaryembodiment, the cross-linked polyacrylic acid polymer is present in a range of 2.5 - 3.5% by total weightof the formulation. The amount of cross-linked polyacrylic acid polymer below 2.5% by total weight of theformulation, results in gelation, while amount above 3.5% by by total weight of the formulation, results ininsoluble Carbopol.
[0043] (c) Optionally Pharmaceutically Active Agent - The formulation may optionally comprisea pharmaceutically active agent that is uniformly dispersed or dissolved within the deep eutectic solventcross-linked polyacrylic acid polymer eutectogel template to enable controlled and sustained drug release.In an exemplary embodiment, pharmaceutically active agent used in the present invention may be selectedfrom a group comprising, such as, but not limited to, anaesthetic agent, anti-inflammatory agent, antibioticagent, antifungal agent, or a combination thereof. In a preferred embodiment, the anaesthetic agent is as apharmaceutically active agent in the present invention. In another exemplary embodiment, the anaestheticagent used in the present invention may be selected from a group comprising such as, but not limited to,lidocaine.
[0044] In another exemplary embodiment; the anti-inflammatory agent may be selected from a groupcomprising such as, but not limited to Ibuprofen.
[0045] In another exemplary embodiment; the antibiotic agent may be selected from a groupcomprising such as, but not limited to Ciprofloxacin.
[0046] In another exemplary embodiment; the antifungal agent may be selected from a groupcomprising such as, but not limited to Fluconazole.
[0047] In another exemplary embodiment, the pharmaceutically active agent is present in a rangeof 0.1 - 1.0% by total weight of the formulation.
[0048] In an embodiment, as shown in Figure 1, the present invention also relates to a method forpreparing cross-linked polyacrylic acid polymer integrated eutectogel formulation. The method comprisesof the following steps:(a) preparing a deep eutectic solvent by mixing a hydrogen bond acceptor with a hydrogen bond donorin a molar ratio ranging from 1:2;(b) heating the prepared mixture at a temperature ranging from 70°C to 90°C for 1 - 3 hours until aclear and homogeneous stable liquid is formed;(c) adding cross-linked polyacrylic acid polymer in the mixture obtained in step (b) in a molar ratio of0.007 0.10 under constant stirring to obtain a uniform dispersion;(d) heating the mixture obtained in step (c) a temperature ranging from 110°C to 140°C for 20-40minutes;(e) optionally dissolving 0.1 - 1.0% of pharmaceutically active agent in the mixture obtained in step(b) by stirring to ensure complete solubilization and(f) allowing the mixture obtained in step (d) to cool to room temperature, forming a cross-linkedpolyacrylic acid polymer integrated eutectogel formulation.
[0049] In an exemplary embodiment, a deep eutectic solvent serves as the solvent medium providinghigh solubilization power for hydrophobic or poorly soluble drugs, thermal stability, low volatility, andbiocompatibility.
[0050] In an exemplary embodiment, the deep eutectic solvent is prepared using a combination of ahydrogen bond acceptor and a hydrogen bond donor.
[0051] In another exemplary embodiment, deep eutectic solvent used in the present invention may beselected from a group comprising such as, but not limited to, Ethaline.
[0052] In a preferred embodiment, Ethaline comprises of choline chloride and ethylene glycol in aratio of 1:1.5-2.5.
[0053] In an exemplary embodiment, pharmaceutically active agent used in the present invention maybe selected from a group comprising, such as, but not limited to, anaesthetic agent, analgesic agent, anti-inflammatory agent, antibiotic, antifungal agent, or a combination thereof.
[0054] In another exemplary embodiment, the anaesthetic agent is used as a pharmaceutically activeagent in the present invention.
[0055] In a preferred embodiment, anaesthetic agent used in the present invention is selected from agroup comprising such as, but not limited to, lidocaine.
[0056] In an exemplary embodiment, the formulation comprises of cross-linked polyacrylic acidpolymer serving as a physical cross-linking polymer to form the gel network. In an exemplary embodiment,the cross-linked polyacrylic acid polymer may be selected from a group comprising such as, but not limitedto, carbopol.
[0057] In a preferred embodiment, carbopol 940 is used as cross-linked polyacrylic acid polymer inthe present invention. In another exemplary embodiment, the cross-linked polyacrylic acid polymer ispresent in a range of 2.5 - 3.5% by total weight of the formulation.
[0058] In a preferred embodiment, the deep eutectic solvent of step (a) is prepared by mixing ahydrogen bond acceptor with a hydrogen bond donor in a molar ratio ranging from 1:2 and thereafterheating the prepared mixture at a temperature of 80°C for 2 hours.
[0059] In a preferred embodiment, mixture obtained in step (c) is heated at a temperature of 130°Cfor 30 minutes.
[0060] The following illustrates example for method of preparation of cross-linked polyacrylic acidpolymer integrated eutectogel formulation and should not be construed to limit the scope of the invention.EXAMPLE
[0061] The deep eutectic solvent (ethaline) is prepared by mixing choline chloride (>98%) as thehydrogen bond acceptor with ethylene glycol (>98%) as the hydrogen bond donor in a 1:2 molar ratio. Themixture is heated at 80°C for 2 hours, forming a clear and homogeneous stable liquid. After preparing thedeep eutectic solvent, varying amounts of carbopol 940 are added to the deep eutectic solvent; however,eutectogel formation occurred only when the carbopol content reached approximately 3 wt%, below whichgelation is not achieved. The mixture is then heated at 130°C for 30 minutes. Thereafter, the mixture isallowed to cool to room temperature, forming the stable eutectogel. For drug loading, lidocaine isincorporated into the eutectogel by direct dissolution into the deep eutectic solvent phase. A known amountof lidocaine (3 mg) is dissolved in 3 mL of ethaline under magnetic stirring to ensure completesolubilization. Carbopol 940 was then gradually incorporated into the drug-loaded deep eutectic solventsolution under constant stirring to obtain a uniform dispersion. The mixture is then gently heated undercontinuous stirring until a clear and uniform gel is formed. The resulting drug-loaded eutectogel is allowedto cool to room temperature and stabilised overnight before further evaluation.
[0062] In an embodiment, the eutectogel provides a sustained release profile wherein approximately90% of the loaded drug is released over a period of approximately 24 hours.
[0063] In an embodiment, the cross-linked polyacrylic acid polymer integrated eutectogel formulationprepared in the present invention exhibits several properties:
[0064] Self-healing behaviour: The eutectogel exhibits autonomous self-healing capability at roomtemperature without the application of any external force or stimulus. The self-healing behaviour isattributed to the dynamic and reversible nature of the supramolecular interactions, particularly hydrogenbonding, between the deep eutectic solvent and the carbopol. When two pieces of the eutectogel are broughtinto contact, they rapidly heal and merge into a single integrated structure. The self-healing capability isconfirmed through rheological measurements wherein the storage modulus and loss modulus recover totheir original values within seconds after removal of high strain conditions.
[0065] Injectability: The eutectogel exhibits excellent injectability through a standard gauge needle,such as a 21-gauge needle. The eutectogel can be smoothly delivered through the needle while maintainingits gel-like consistency after injection. The injectability is attributed to the thixotropic behaviour of theeutectogel, wherein the gel network undergoes structural breakdown under increasing strain andsubsequently recovers upon removal of the strain. This property enables minimally invasive localised drugdelivery applications.
[0066] Thermal stability: The eutectogel exhibits thermal stability up to approximately 150°C, withthe first stage of decomposition occurring at approximately 243°C. The glass transition temperature of theeutectogel is near physiological temperature, with an inflection point at approximately 41°C, suggestingthermoresponsive behaviour advantageous for drug delivery applications where controlled release at bodytemperature is desired. The absence of endothermic or exothermic melting or crystallisation peaks confirmsthe amorphous nature and thermodynamic stability of the eutectogel.
[0067] Mechanical properties: The eutectogel exhibits dominant elastic (solid-like) properties withthe storage modulus remaining consistently higher than the loss modulus throughout the frequency range.The storage modulus is approximately 104 Pa and the loss modulus is approximately 103 Pa. The yield pointof the eutectogel, where the material transitions from solid-like to liquid-like behaviour, occurs atapproximately 40% strain.
[0068] Long-term stability: The eutectogel exhibits a homogeneous, transparent appearance andlong-term stability without phase separation for more than one year at ambient temperature. The absenceof cracks or discontinuities in the morphological structure supports the effective entrapment of the eutecticphase within the gel structure.
[0069] Antibacterial activity: The eutectogel exhibits antibacterial activity against both Grampositivebacteria such as Staphylococcus aureus and Gram-negative bacteria such as Escherichia coli. Thedrug-loaded eutectogel exhibits enhanced antibacterial efficacy compared to the neat eutectogel due to thesustained release and improved solubilization of the pharmaceutically active agent.
[0070] Cytocompatibility: The eutectogel exhibits cytocompatibility with cell viability exceeding70% at therapeutic concentrations, which is the threshold generally considered to indicate non-cytotoxicmaterials suitable for biomedical applications. The drug-loaded eutectogel exhibits superior cellcompatibility compared to the neat eutectogel.
[0071] Hemocompatibility: The eutectogel exhibits hemocompatibility with hemolysis below 5%,which is below the threshold established by safety standards for biomedical materials. The eutectogel doesnot disrupt erythrocyte membranes, confirming its suitability for clinical requirements and biomedical use.
[0072] In an embodiment, cross-linked polyacrylic acid polymer integrated eutectogel formulationprepared in the present invention is stored in an airtight container and kept in a cool and dry place awayfrom direct sunlight to maintain stability and extend shelf life.
[0073] In another embodiment, the cross-linked polyacrylic acid polymer integrated eutectogelformulation is formulated for various drug delivery applications by adjusting the type and concentration ofthe pharmaceutically active agent.
[0074] In another embodiment, the cross-linked polyacrylic acid polymer integrated eutectogelformulation is suitable for transdermal delivery, localised delivery, wound care applications, or injectabledepot formulations.
[0075] In another embodiment, the cross-linked polyacrylic acid polymer integrated eutectogelformulation prepared in the present invention is applied topically to the skin or injected locally to providecontrolled and sustained drug release. The cross-linked polyacrylic acid polymer integrated eutectogelformulation may be applied once or twice daily depending on the therapeutic requirements. The crosslinkedpolyacrylic acid polymer integrated eutectogel formulation delivers sustained drug release overapproximately 24 hours, with approximately 90% of the loaded drug released during this period. The releaseprofile exhibits an initial burst phase during the first 10-15 minutes, followed by a sustained and gradualincrease in drug release. The release kinetics follow the Korsmeyer-Peppas model, indicating a combinationof diffusion and polymer matrix relaxation mechanisms.
[0076] The following illustrates experimental data and should not be construed to limit the scope ofthe invention.EXPERIMENTAL DATACharacterization Results
[0077] Spectroscopic Analysis:
[0078] As illustrated in Figure. 2, the spectral and microscopic profile of the prepared eutectogel isillustrated. The FT-IR spectrum confirms the successful formation of the eutectogel through intermolecularinteractions, particularly hydrogen bonding within the deep eutectic solvent system. The peaks observed at3297, 2875, 2938, 1478, 1083, 1036, and 953 cm-1 correspond to various functional group vibrations. Thebroad band at 3297 cm-1 is associated with intermolecular hydrogen bonding and O-H stretching ofalcoholic groups. Peaks at 2875 and 2938 cm-1 are attributed to C-H stretching of choline chloride. Thepeak at 1478 cm-1 corresponds to C-H bending of -CH2 groups. Peaks at 1083 and 1036 cm-1 indicate C-Ostretching in primary alcohols. The peak at 953 cm-1 is linked to N-C-C bending, characteristic of thequaternary ammonium group in the deep eutectic solvent. Additionally, peaks at 2112 and 1650 cm-1 areassigned to C=O stretching vibrations in carbopol, which are influenced by hydrogen bonding interactions.
[0079] Morphological Analysis:
[0080] The SEM micrographs in Figure. 2 reveal a highly interconnected and homogeneous networkstructure with well-defined, tightly packed domains exhibiting smooth contours and continuous interfaces,indicating uniform distribution of the polymeric matrix within the ethaline system. The absence of cracksor discontinuities supports the effective entrapment of the eutectic phase within the gel structure, confirmingthe formation of a stable three-dimensional network essential for maintaining mechanical integrity andproviding a sustained drug release platform.
[0081] Thermal Analysis:
[0082] Referring to Figure. 3, the thermal analysis of the prepared eutectogel is illustrated. Figure3(a) shows the TGA curve demonstrating the thermal stability of the eutectogel. The first stage ofdecomposition occurs at 243°C with a mass loss of approximately 53%, followed by completedecomposition at 316°C. This thermal profile indicates that the eutectogel maintains stability well abovephysiological temperatures, making it suitable for biomedical applications. Figure 3(b) shows the DSCthermogram exhibiting a clear glass transition temperature (Tg) with onset at 38.8°C, midpoint at 40.8°C,inflection point at 41.1°C, and endset at 43.9°C. The corresponding change in heat capacity (ΔCp) wascalculated as 0.191 J·g-1·K-1. The distinct Tg indicates the amorphous nature of the prepared eutectogel,confirming the formation of a homogeneous structure without crystalline domains. The absence ofendothermic or exothermic melting or crystallisation peaks during heating suggests that the system isthermodynamically stable and well-mixed at the molecular level. The Tg near physiological temperatureimplies that the prepared eutectogel exhibits thermoresponsive behaviour, which is advantageous for drugdelivery applications where controlled release at body temperature is desired. During the cooling cycle, anexothermic peak was observed at 47.7°C, associated with a heat release of -11.65 J·g-1, which is attributedto partial reorganisation of the hydrogen-bonding network or local microphase structuring within theeutectogel.
[0083] Rheological Analysis
[0084] Referring now to Figure. 4, the rheological analysis of the prepared eutectogel is illustrated.Figure. 4(a) shows the frequency sweep analysis conducted at 0.1% strain in the frequency range of 0.1 to200 rad / s at 37°C. Throughout the frequency range, the storage modulus (G') remained consistently higherthan the loss modulus (G''), indicating dominant elastic (solid-like) properties and confirming the formationof a robust three-dimensional gel network. The weak frequency dependence of G', with its slight increaseat higher frequencies, suggests a stable and interconnected gel network. The near-plateau behaviour of G''further supports this stability, implying minimal structural rearrangements under varying oscillatoryfrequencies. Figure. 4(b) shows the oscillatory strain sweep analysis conducted at a fixed angular frequency(1 rad / s) at 37°C. At low strains, G' is greater than G'', demonstrating the integrity of the eutectogel withinthe linear viscoelastic region. However, beyond a critical strain of approximately 40%, G' and G'' converge,marking the yield point where the material transitions from a solid-like to a liquid-like state. This behaviourindicates that the gel network undergoes structural breakdown under increasing strain. Beyond the yieldpoint, G'' exceeds G', highlighting the dominance of viscous behaviour as the gel flows. Figure. 4(c) showsthe alternate step strain sweeps demonstrating the self-healing behaviour of the eutectogel. The G' and G''were monitored by applying a cyclic step-strain protocol, where low strain (1%) and high strain (100%) ata constant angular frequency (10 rad·s-1) were alternately applied over five cycles, maintaining each strainlevel for approximately 60 seconds. Under low strain (1%), the prepared eutectogel displayed a high andstable G' (approximately 1000 Pa) and a lower G'' (approximately 200 Pa), indicating a predominantlyelastic (solid-like) nature. Upon application of high strain (100%), both moduli decreased sharply,demonstrating disruption of the gel network due to deformation. However, when the strain was againreduced to 1%, both G' and G'' regained their original values within seconds, confirming the reversible selfhealingbehaviour of the eutectogel. The eutectogel successfully restored its mechanical structure overmultiple cycles without significant loss of elasticity or stiffness, highlighting its robust network structuregoverned by reversible non-covalent interactions such as hydrogen bonding.
[0085] Referring to Figure. 5, the self-healing and injectability properties of the prepared eutectogelare illustrated. Figure 5(a) shows photographs of the self-healing process wherein two pieces of theeutectogel, one neat (transparent) and one stained with methylene blue, were brought into contact at roomtemperature without the application of any external force. The eutectogel pieces rapidly healed once incontact, merging into a single integrated eutectogel again without any external stimulus. This macroscopicself-healing behaviour confirms the dynamic and reversible nature of the supramolecular interactionsbetween the deep eutectic solvent and the carbopol. Figure 5(b) shows the injectability of the eutectogelthrough a 21-gauge needle. The eutectogel can be easily injected through the needle and retains its gelstructure after injection. The ability to write letters using the same needle demonstrates the excellentinjectability and structural integrity of the eutectogel, confirming its suitability for minimally invasivelocalised drug delivery applications.
[0086] In vitro drug release study
[0087] Referring to Figure. 6, the cumulative drug release profile of lidocaine from the eutectogelformulation is illustrated.
[0088] To investigate the release behaviour of lidocaine from the eutectogel, the in vitro release datawere analysed using various mathematical models including zero-order, first-order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas, and Weibull models. The zero-order model, which describes a constantrelease rate regardless of drug concentration, indicated a possibility of sustained-release behaviour over thetime course, making the system potentially suitable for prolonged therapeutic applications. The first-ordermodel, which postulates that drug release is dependent on the concentration remaining in the eutectogel,demonstrated a decreasing release rate over time, implying a concentration-driven release process. TheHiguchi model suggested a diffusion-controlled release mechanism consistent with Fickian diffusion,where the drug molecules migrate through a hydrated gel matrix. The Hixson-Crowell model, whichaccounts for changes in the surface area and structure of the gel during dissolution, suggested that therelease process also involves gel erosion or restructuring in addition to diffusion. The Korsmeyer-Peppasmodel was employed to assess the drug release mechanism when both diffusion and erosion were involved,indicating a non-Fickian or anomalous transport behaviour implying a coupling of diffusion and polymermatrix relaxation. The Weibull model provided a flexible empirical representation of the release profile.Among all models evaluated, the Korsmeyer-Peppas model provided the best fit with the highest R2 valueand lowest RMSE, AIC, and BIC values, confirming that the release mechanism involves a combination ofdiffusion and polymer matrix relaxation.
[0089] The in vitro drug release study was conducted in PBS (pH 7.4) at 37°C over 24 hours (1440minutes). The release profile exhibited an initial burst phase during the first 10-15 minutes, followed by asustained and gradual increase in drug release up to 1440 minutes. This biphasic pattern suggests thatlidocaine is released via a combination of diffusion through the eutectogel and swelling or erosion of thegel structure. The initial rapid release is attributed to the drug located near or on the eutectogel surface,while the subsequent slower release is governed by diffusion from the eutectogel interior. After 24 hours,approximately 90% of the loaded drug was released, indicating the good controlled release capability of theeutectogel. Kinetic analysis showed that the Korsmeyer-Peppas model provided the best fit with the highestR2 value and lowest RMSE, AIC, and BIC values, indicating a combination of diffusion and polymer matrixrelaxation mechanisms.
[0090] Table
[0091] Table 1 illustrates kinetic fitting parameters of lidocaine release from eutectogel using variousmathematical models.
[0092] Antibacterial efficacy
[0093] Referring to Figure. 7, the zone of inhibition assay of neat eutectogel (Sample 1) and drugloadedeutectogel (Sample 2) against E. coli and S. aureus is illustrated. The antibacterial efficacy wasassessed using the disk diffusion method against E. coli and S. aureus. For E. coli, the neat eutectogelshowed a zone of inhibition of 2.2±0.1 cm, while the drug-loaded eutectogel achieved a larger zone of2.5±0.1 cm. For S. aureus, the neat eutectogel exhibited a zone of 2.6±0.1 cm, and the drug-loadedeutectogel displayed enhanced efficacy with a 2.9±0.1 cm zone. Kirby-Bauer disk diffusion method, LBagar plates (25 mL in 100 mm Petri dishes), 5 mm diameter paper disks pre-soaked for 24 hours,ciprofloxacin (0.5 μg·mL-1) as positive control, incubation at 37°C for 24 hours, ImageJ software for zonemeasurement
[0094] Both samples demonstrated visible inhibition zones, confirming theirbacteriostatic / bactericidal potential. For E. coli, Sample 1 showed a zone of inhibition of 2.2±0.1 cm, whileSample 2 achieved a larger zone of 2.5±0.1 cm, closely approaching that of the positive control. For S.aureus, Sample 1 exhibited a zone of 2.6±0.1 cm, and Sample 2 displayed enhanced efficacy with a 2.9±0.1cm zone. This indicates that both neat eutectogel and drug-loaded eutectogel possess broad-spectrumantibacterial properties, with the drug-loaded formulation showing a synergistic enhancement, likely dueto the sustained release and improved solubilization of lidocaine within the eutectogel. The increasedsusceptibility of S. aureus compared to E. coli is attributed to the structural differences in the bacterial cellwalls, where the thicker peptidoglycan layer of Gram-positive bacteria is more susceptible to eutecticinducedmembrane destabilization.
[0095] Cytocompatibility Evaluation
[0096] Referring to Figure. 8, the in vitro cytotoxicity assay of neat eutectogel (Sample 1) and drug15loaded eutectogel (Sample 2) is illustrated. The MTT assay was conducted on L929 cells to assessbiocompatibility. Cell viability was found to be dose-dependent, increasing with dilution. At the highestconcentration (1 mg·mL-1), Sample 1 and Sample 2 showed moderate viabilities of approximately 45% andapproximately 40%, respectively. However, at lower concentrations (≤0.1 mg·mL-1), both samples achievedsignificantly higher viabilities: Sample 1 approximately 75-80% and Sample 2 approximately 90-95%.These results confirm that both formulations are non-cytotoxic at therapeutic levels, with the drug-loadedeutectogel (Sample 2) exhibiting slightly superior cell compatibility. The results indicate that the gel didnot release toxic components and demonstrated excellent biocompatibility, which are attributed to mildanti-inflammatory properties or its controlled release of lidocaine via the eutectogel. L929 cells cultured in96-well plates at 1x105 cells·mL-1, incubated for 24 h at 37°C in 5% CO2, 20 μL MTT solution (5 mg / mLin PBS), 4 h incubation for formazan crystal formation, 100 μL solubilization solution, 30 min shaking,absorbance at 570 nm, Multiskan GO microplate reader (Thermo Scientific, USA)
[0097] Hemocompatibility Assessment
[0098] Referring to Figure. 9, The hemolysis assay was performed. PBS (negative control), neateutectogel, and drug-loaded eutectogel exhibited negligible hemolysis (approximately 0%), while TritonX-100 (positive control) caused complete hemolysis (approximately 100%). Both eutectogel formulationsdemonstrated hemolysis values well below the 5% threshold, confirming excellent hemocompatibility.Whole blood centrifuged at 2000 rpm for 20 min, RBCs washed thrice with 1x PBS, 10% (v / v) workingRBC suspension (1 mL RBCs in 9 mL PBS), centrifugation at 10,000 rpm for 15 min, absorbance at 540nm, Multiskan GO microplate reader (Thermo Scientific, USA), 1% Triton X-100 as positive control. Thehemolytic potential was evaluated using freshly collected human erythrocytes incubated with theformulations for 5 hours, followed by UV-Vis spectrophotometric analysis.
[0099] Figure. 9 shows the visual comparison of RBCs before and after centrifugation and thequantitative hemolysis percentage. Triton X-100 (positive control) caused complete hemolysis(approximately 100%), while PBS (negative control), neat eutectogel (Sample 1), and drug-loadedeutectogel (Sample 2) exhibited negligible hemolysis (approximately 0%), far below the ISO 10993-4(ASTM F756-2008) threshold of 5%, indicating that the eutectogel is considered a safe material and meetsclinical safety standards. The high hemocompatibility of both samples suggests that the eutectogel, with orwithout drug, does not disrupt erythrocyte membranes, further supporting their suitability for clinicalrequirements and biomedical use, particularly in wound dressings or as injectable hydrogels for local drugdelivery.
[0100] The present invention exhibits the following advantages:- The formulation provides a stable, transparent, biocompatible, self-healing, and injectable geltemplate through physical cross-linking, eliminating the need for chemical cross-linkers and toxiccatalysts.- The deep eutectic solvent provides high solubilization power for hydrophobic or poorly solubledrugs, enabling enhanced drug loading capacity and bioavailability compared to conventionalwater-based gels.- The formulation exhibits self-healing behaviour through dynamic noncovalent interactions,enabling the eutectogel to restore structural integrity after damage while maintaining functionalperformance.- The formulation exhibits excellent injectability through a standard gauge needle, enablingminimally invasive localised drug delivery applications.- The formulation delivers controlled and sustained drug release over approximately 24 hours, withrelease kinetics following the Korsmeyer-Peppas model indicating a combination of diffusion andpolymer matrix relaxation mechanisms.- The formulation exhibits antibacterial activity against both Gram-positive and Gram-negativebacteria, making it suitable for wound care and transdermal delivery applications.- The formulation exhibits cytocompatibility with cell viability exceeding 70% at therapeuticconcentrations and hemocompatibility with hemolysis below 5%, confirming its biocompatibilityfor biomedical applications.- The formulation exhibits long-term stability without phase separation for more than one year atambient temperature.
[0101] While this invention has been described in connection with what is presently considered to bethe most practical and preferred embodiment, it is to be understood that the invention is not limited to thedisclosed embodiments, but, on the contrary, is intended to cover various modifications and equivalentarrangements included within the scope of the appended claims.
Claims
1. A cross-linked polyacrylic acid polymer integrated eutectogel formulation for transdermal and localised drug delivery, comprising: - a deep eutectic solvent in a range of 95.5 - 97.4% by total weight of the formulation - a cross-linked polyacrylic acid polymer in a range of 2.5 - 3.5% by total weight of formulation; and - optionally a pharmaceutically active agent in a range of 0.1 - 1.0% by total weight of formulation.
2. The eutectogel formulation as claimed in claim 1; wherein the deep eutectic solvent comprising a hydrogen bond acceptor and a hydrogen bond donor in a molar ratio ranging from 1:1.5 to 1:2.5;3. The eutectogel formulation as claimed in claim 1, wherein the deep eutectic solvent is Ethaline comprising choline chloride as the hydrogen bond acceptor and ethylene glycol as the hydrogen bond donor in a molar ratio of 1:2.
4. The eutectogel formulation as claimed in claim 1, wherein the cross-linked polyacrylic acid polymer is carbopol 940.
5. The eutectogel formulation as claimed in claim 1, wherein the pharmaceutically active agent is selected from a group comprising of an anaesthetic agent; anti-inflammatory agent, antibiotic agent, antifungal agent, or a combination thereof.
6. The eutectogel formulation as claimed in claim 5, wherein the anaesthetic agent is selected from a group comprising such as, but not limited to, lidocaine.
7. The eutectogel formulation as claimed in claim 1, wherein the cross-linked polyacrylic acid polymer is physically cross-linked with the deep eutectic solvent to form a stable, biocompatible, self-healing, and injectable gel template without requiring chemical cross-linkers to exhibits self-healing behaviour at room temperature through dynamic and reversible hydrogen bonding interactions between the deep eutectic solvent and the cross-linked polyacrylic acid polymer.
8. The eutectogel formulation as claimed in claim 1, wherein the formulation provides sustained drug release wherein approximately 90% of the loaded drug is released over a period of approximately 24 hours.
9. The eutectogel formulation as claimed in claim 1, wherein the formulation exhibits thermal stability up to approximately 150°C with a glass transition temperature near physiological temperature at approximately 41°C.
10. A method for preparing the cross-linked polyacrylic acid polymer integrated eutectogel formulation as claimed in claim 1, comprising steps of: a) preparing a deep eutectic solvent by mixing a hydrogen bond acceptor with a hydrogen bond donor in a molar ratio ranging from 1:1.5 to 1:2.5; b) heating the prepared mixture of step (a) at a temperature ranging from 70°C to 90°C for 1-3 hours to form a clear and homogeneous stable liquid; c) adding cross-linked polyacrylic acid polymer in the mixture obtained in step (b) in the molar ratio of 0.007-0.10 under constant stirring to obtain a uniform dispersion; d) optionally dissolving of 0.1 - 1.0% of pharmaceutically active agent in the mixture obtained in step (c) by stirring to ensure complete solubilization; e) heating the mixture obtained in step (c) or step (d) at a temperature ranging from 110°C to 140°C for 20- 40 minutes; and f) allowing the mixture obtained in step (e) to cool to room temperature, forming the cross-linked polyacrylic acid polymer integrated eutectogel formulation.
